Investors reposed faith in our future growth prospects: Syngene

Readying to list its shares after a bumper 32-times over-subscribed IPO, biotechnology major Biocon's research arm Syngene on Thursday said the investors have reposed faith in its future growth prospects.

SEBI's insider trading norms 'draconian': Biocon's Shaw

In a sharp criticism of regulator SEBI's new insider trading norms, industry leader and Biocon chief Kiran Mazumdar Shaw Friday said these rules have "draconian intent" and will kill the ESOPs.

Biocon sets price band at Rs 240-250 for research arm's IPO

Biotechnology major Biocon Ltd has set the price band at Rs 240-250 per equity share for the initial public offering of its research arm Syngene International Ltd.

Syngene gets nod to raise foreign investment to 44%
Syngene gets nod to raise foreign investment to 44%

Syngene, a subsidiary of Biocon, on Monday said it has received the Foreign Investment Promotion Board (FIPB) approval for raising foreign investment in the company to 44 percent from the earlier approved 10 percent.

Govt approves FDI worth Rs 4,000 cr in pharma sector
Govt approves FDI worth Rs 4,000 cr in pharma sector

Proposals for foreign direct investment amounting to around Rs 4,000 crore by four pharma and medical devices firms, including Torrent Pharmaceuticals and Biocon's research services arm Syngene, were on Wednesday approved by the government.

Biocon's arm Syngene gets SEBI nod for IPO

Syngene International, research arm of biotechnology major Biocon, has received capital markets regulator SEBI's approval to launch an initial public offer (IPO).

Biocon, Mylan drug discovery programme makes progress

Biocon shares were trading at Rs 425.90 apiece, up 0.16%, on the BSE.

Biocon Q4 consolidated net surges 78%

During the quarter, Biocon reported exceptional gain of Rs 105.06 crore on account of share sale in its research services subsidiary Syngene.

Biocon files IPO prospectus for R&D arm Syngene

Biotech firm Biocon Ltd has filed a prospectus for the initial public offering of its USD 600 million research and development arm, Syngene, it said on Thursday.

Biocon files prospectus for Syngene IPO to raise Rs 600 cr

Biotechnology major Biocon Wednesday filed prospectus with market regulator SEBI for the initial public offer of its research arm Syngene through which aims to raise around Rs 600 crore that will be used to fund its R&D programmes.

Biocon arm Syngene appoints Peter Bains as CEO

Biotechnology major Biocon's custom research arm Syngene has appointed Peter Bains as its Chief executive Officer (CEO).

Biocon arm to have 40-acre new plant in Mangalore SEZ

Biocon's research services arm Syngene International would set up a new plant at Mangalore SEZ to manufacture pharma ingredients and agro chemicals.

Mazumdar-Shaw honoured by Federation University Australia

Biocon Chairperson Kiran Mazumdar-Shaw has been honoured by Federation University Australia (FedUni) by dedicating a road at the University's Mt Helen Campus and naming it as 'Mazumdar Drive.'

Biocon to invest 10% of biopharma revenues on R&D next fiscal

Continuing it emphasis on innovation, biotechnology major Biocon plans to spend 10 percent of its annual biopharma revenue on research and development in the next fiscal year.

Biocon completes 10% stake sale in Syngene

Biotechnology major Biocon on Monday concluded sale of 10 percent stake in its research arm Syngene for Rs 380 crore to IVF Trustee Company Private Ltd.

'Biocon planning to set up manufacturing unit in Vizag'

Pharmaceutical giant Biocon is contemplating setting up a manufacturing facility in Visakhapatnam, Andhra Pradesh government said Sunday.

Biocon Q2 Net flat at Rs 102 crore

Biotechnology major Biocon on Wednesday reported a flat growth in its consolidated net profit at Rs 102.05 crore for the quarter ended September 30, 2014.

Biocon, Bristol-Myers Squibb extend drug discovery partnership

Biotechnology major Biocon and US-based Bristol-Myers Squibb today announced a five-year extension of their drug discovery and development partnership in India.

Cutting drug prices will deter firms from manufacturing: Shaw

Kiran Mazumdar Shaw raised concerns that the new government's intention to bring down prices of essential drugs could deter manufacturing of such medicines.

Kiran Mazumdar-Shaw is the new chairperson of IIM-B

India`s biotechnology queen Kiran Mazumdar-Shaw is the new chairperson of the prestigious Indian Institute of Management-Bangalore (IIM-B) as incumbent Mukesh Ambani of Reliance Industries stepped down.